Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
Deal Dive: Cutting through the noise in a category clouded by catastrophic failure

From TechCrunch

By Rebecca Szkutak

July 29, 2023

Deal Dive: Cutting through the noise in a category clouded by catastrophic failure

Building a startup is hard enough but growing one in a category marred with Theranos-sized stigma is a new level of challenge. Vital Bio seems up for the test.

The Toronto-based startup is building a machine, VitalOne, that can perform more than 50 blood tests — covering nearly all of those considered routine — and get patient results back in 20 minutes, not multiple days. Co-founder and CEO Vasu Nadella said that he got interested in the space because he and his co-founders have watched family members deal with chronic illness and know that being able to get quick diagnostic results is crucial for treatment.

Plus, Nadella wanted to know why companies couldn’t seem to get the solution to this problem right. While Theranos failed for a variety of reasons, the other companies trying to build these quicker blood diagnostic tools had yet to ship products. He thought maybe he could crack the code.

The startup launched in 2019 and built quietly until it debuted its device at the American Association of Clinical Chemistry’s annual meeting — the industry’s “Super Bowl” — last Monday. Vital Bio also announced that it had raised $48 million in venture funding from Labcorp, Inovia Capital, Lachy Groom and Sam Altman, among others.

Nadella said the company has focused on making sure that its device produces accurate results and that when it does drift, they know how to prevent it from impacting the final diagnosis. He said the company waited to start talking about what it was up to until it felt it had enough to back up its claims.

Most Recent

Travis Kalanick’s robotics company raises $1.7B, led by a16z

Travis Kalanick’s robotics company raises $1.7B, led by a16z

Uber is also investing in Travis Kalanick's company Atoms, which has made gauzy claims about using industrial AI to modernize the world.

Jul 22, 2026

Arcee, a US open source AI lab, says Chinese models are not inherently dangerous

Arcee, a US open source AI lab, says Chinese models are not inherently dangerous

As Chinese AI models grow in capability and popularity among U.S. companies, the arguing over what should be done about them has reached a fever pitch.

Jul 22, 2026

Cascade raises $3.5M to help construction firms find and win projects

Cascade raises $3.5M to help construction firms find and win projects

a16z Speedrun, Ada Ventures, and Snowball VC have invested in Cascade's $3.5 million seed round.

Jul 22, 2026

The browser wars aren’t about search anymore — here are the best alternatives to Chrome and Safari

The browser wars aren’t about search anymore — here are the best alternatives to Chrome and Safari

We’ve compiled an overview of some of the top alternative browsers available today aiming to challenge Chrome and Safari.

Jul 22, 2026

Similar Posts

Miraqules will showcase its blood clotting technology at TechCrunch Disrupt 2025

Miraqules will showcase its blood clotting technology at TechCrunch Disrupt 2025

India-based Miraqules developed a nanotechnology that mimics blood clotting proteins to quickly stop heavy bleeding.

Oct 27, 2025

What startup founders need to know about AI heading into 2024

What startup founders need to know about AI heading into 2024

Now that the OpenAI leadership saga has died down, startup founders building with AI can get back to work building the future. If that’s you, TechCrunch+ has a pile of notes, opinion pieces and forward-looking stories with your name on them. Sure, TechCrunch+ is a lot more than AI-related coverage, but we are also going […]

Nov 26, 2023

FDA approval, fundraising, and the reality of building in healthcare according to BioticsAI founder

FDA approval, fundraising, and the reality of building in healthcare according to BioticsAI founder

BioticsAI CEO Robhy Bustami joined Isabelle Johannessen on Build Mode to discuss how the company has navigated a highly regulated space and kept the team motivated while cutting through all the red tape.

Apr 30, 2026

The most interesting startups right now want to get you off your phone

The most interesting startups right now want to get you off your phone

Watch as the Equity podcast breaks down Anthropic's surprise IPO filing, the founders building startups to get you off your screen, and the token bubble that's starting to burst.

Jun 5, 2026

Most Recent

Travis Kalanick’s robotics company raises $1.7B, led by a16z

Travis Kalanick’s robotics company raises $1.7B, led by a16z

Uber is also investing in Travis Kalanick's company Atoms, which has made gauzy claims about using industrial AI to modernize the world.

Jul 22, 2026

Arcee, a US open source AI lab, says Chinese models are not inherently dangerous

Arcee, a US open source AI lab, says Chinese models are not inherently dangerous

As Chinese AI models grow in capability and popularity among U.S. companies, the arguing over what should be done about them has reached a fever pitch.

Jul 22, 2026

Cascade raises $3.5M to help construction firms find and win projects

Cascade raises $3.5M to help construction firms find and win projects

a16z Speedrun, Ada Ventures, and Snowball VC have invested in Cascade's $3.5 million seed round.

Jul 22, 2026

The browser wars aren’t about search anymore — here are the best alternatives to Chrome and Safari

The browser wars aren’t about search anymore — here are the best alternatives to Chrome and Safari

We’ve compiled an overview of some of the top alternative browsers available today aiming to challenge Chrome and Safari.

Jul 22, 2026

Similar Posts

Miraqules will showcase its blood clotting technology at TechCrunch Disrupt 2025

Miraqules will showcase its blood clotting technology at TechCrunch Disrupt 2025

India-based Miraqules developed a nanotechnology that mimics blood clotting proteins to quickly stop heavy bleeding.

Oct 27, 2025

What startup founders need to know about AI heading into 2024

What startup founders need to know about AI heading into 2024

Now that the OpenAI leadership saga has died down, startup founders building with AI can get back to work building the future. If that’s you, TechCrunch+ has a pile of notes, opinion pieces and forward-looking stories with your name on them. Sure, TechCrunch+ is a lot more than AI-related coverage, but we are also going […]

Nov 26, 2023

FDA approval, fundraising, and the reality of building in healthcare according to BioticsAI founder

FDA approval, fundraising, and the reality of building in healthcare according to BioticsAI founder

BioticsAI CEO Robhy Bustami joined Isabelle Johannessen on Build Mode to discuss how the company has navigated a highly regulated space and kept the team motivated while cutting through all the red tape.

Apr 30, 2026

The most interesting startups right now want to get you off your phone

The most interesting startups right now want to get you off your phone

Watch as the Equity podcast breaks down Anthropic's surprise IPO filing, the founders building startups to get you off your screen, and the token bubble that's starting to burst.

Jun 5, 2026